代谢紊乱治疗市场－全球产业规模、份额、趋势、机会及预测，依疾病类型、治疗类型、地区及竞争情况细分，2020-2030 年

2024 年全球代谢紊乱治疗市场价值为 744 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 7.68%。全球代谢紊乱治疗市场涵盖专注于开发针对代谢紊乱的标靶治疗方法的製药和生物技术产业。这些疾病会破坏人体处理和调节必需营养素的能力，包括糖尿病、肥胖和高血脂等常见疾病，以及苯酮尿症和戈谢氏症等罕见遗传性疾病。

全球代谢疾病发病率的上升，加上基因治疗、酵素替代疗法和下一代减肥药物等标靶治疗的进步，推动了市场的成长。领先的製药公司正在大力投资研发和策略合作。

然而，在该领域营运的公司必须解决监管复杂性、严格的临床审批流程和长期安全问题，才能最大限度地发挥商业潜力。成功将科学创新与法规合规性结合的公司将能够充分利用日益增长的代谢紊乱治疗需求。

主要市场驱动因素

代谢紊乱盛行率上升

主要市场挑战

开发成本高

主要市场趋势

精准医疗和个人化治疗

目录

第 1 章：产品概述

第二章：研究方法

第 3 章：执行摘要

第四章：顾客之声

第 5 章：代谢紊乱治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疾病类型（溶小体贮积症、糖尿病、肥胖、遗传代谢紊乱、高胆固醇血症、其他）
  • 依治疗类型（酵素替代疗法、细胞移植、小分子疗法、底物减少疗法、基因疗法、药物疗法）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美代谢紊乱治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第七章：欧洲代谢紊乱治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太代谢失调治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲代谢紊乱治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲代谢紊乱治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球代谢紊乱治疗市场：SWOT 分析

第 14 章：竞争格局

• Novo Nordisk A/S
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Merck KGaA
• AstraZeneca PLC
• AbbVie Inc
• Johnson & Johnson Services, Inc
• Amgen Inc
• BioMarin International Limited

第 15 章：策略建议

第16章调查会社について・免责事项

Global Metabolic Disorders Therapeutics Market was valued at USD 74.40 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.68% through 2030. The Global Metabolic Disorders Therapeutics Market encompasses the pharmaceutical and biotechnology industries focused on developing targeted treatments for metabolic disorders. These conditions, which disrupt the body's ability to process and regulate essential nutrients, include widespread diseases such as diabetes, obesity, and hyperlipidemia, as well as rare genetic disorders like phenylketonuria and Gaucher's disease.

Market growth is being propelled by the rising global incidence of metabolic diseases, coupled with advancements in targeted therapies, including gene therapy, enzyme replacement therapy, and next-generation weight-loss medications. Leading pharmaceutical firms are investing heavily in R&D and strategic collaborations.

However, companies operating in this sector must address regulatory complexities, stringent clinical approval processes, and long-term safety concerns to maximize commercial potential. Firms that successfully integrate scientific innovation with regulatory compliance will be well-positioned to capitalize on the expanding demand for metabolic disorder therapeutics.

Key Market Drivers

Rising Prevalence of Metabolic Disorders

The increasing global burden of metabolic disorders is a primary force accelerating the growth of the Global Metabolic Disorders Therapeutics Market. As the incidence of diseases such as diabetes, obesity, hyperlipidemia, and rare genetic metabolic disorders rises sharply, the demand for innovative therapeutics, disease management solutions, and preventive interventions continues to grow. Several factors contribute to this trend, each reinforcing the market's expansion and creating new opportunities for pharmaceutical and biotechnology companies.

According to the IDF Diabetes Atlas (2021), 10.5% of the global adult population (ages 20-79) is living with diabetes, with nearly 50% of cases remaining undiagnosed due to limited awareness and screening gaps. Projections indicate that by 2045, the prevalence will rise to 1 in 8 adults, reaching approximately 783 million cases-a 46% increase driven by shifting demographics, urbanization, and lifestyle changes. Notably, over 90% of diabetes cases are classified as Type 2 diabetes, largely influenced by socioeconomic disparities, aging populations, environmental risk factors, and genetic predisposition. This surge in global disease burden is expected to intensify demand for advanced therapeutics, early diagnostic solutions, and digital health interventions, making diabetes management a critical priority for healthcare systems and pharmaceutical innovators.

Key Market Challenges

High Development Costs

The research and development of new therapies for metabolic disorders can be prohibitively expensive. The cost of conducting clinical trials, obtaining regulatory approvals, and ensuring safety and efficacy adds significant financial pressure to pharmaceutical and biotech companies.

Key Market Trends

Precision Medicine and Personalized Therapies

The era of one-size-fits-all treatments is giving way to precision medicine. Genetic profiling, biomarker identification, and patient-specific data are increasingly guiding treatment decisions. Tailored therapies that consider an individual's genetic and metabolic profile promise higher efficacy and reduced side effects in the management of metabolic disorders.

Key Market Players

• Novo Nordisk A/S
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Merck KGaA
• AstraZeneca PLC
• AbbVie Inc
• Johnson & Johnson Services, Inc
• Amgen Inc
• BioMarin International Limited

Report Scope:

In this report, the Global Metabolic Disorders Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolic Disorders Therapeutics Market, By Disease Type:

• Lysosomal Storage Diseases
• Diabetes
• Obesity
• Inherited Metabolic Disorders
• Hypercholesterolemia
• Others

Metabolic Disorders Therapeutics Market, By Therapy Type:

• Enzyme Replacement Therapy
• Cellular Transplantation
• Small Molecule Based Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy

Metabolic Disorders Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Disorders Therapeutics Market.

Available Customizations:

Global Metabolic Disorders Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Metabolic Disorders Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
  • 5.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Metabolic Disorders Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metabolic Disorders Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy Type
  • 6.3.2. Canada Metabolic Disorders Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy Type
  • 6.3.3. Mexico Metabolic Disorders Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy Type

7. Europe Metabolic Disorders Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metabolic Disorders Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy Type
  • 7.3.2. United Kingdom Metabolic Disorders Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy Type
  • 7.3.3. Italy Metabolic Disorders Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy Type
  • 7.3.4. France Metabolic Disorders Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy Type
  • 7.3.5. Spain Metabolic Disorders Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy Type

8. Asia-Pacific Metabolic Disorders Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy Type
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Metabolic Disorders Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy Type
  • 8.3.2. India Metabolic Disorders Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy Type
  • 8.3.3. Japan Metabolic Disorders Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy Type
  • 8.3.4. South Korea Metabolic Disorders Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy Type
  • 8.3.5. Australia Metabolic Disorders Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy Type

9. South America Metabolic Disorders Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metabolic Disorders Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy Type
  • 9.3.2. Argentina Metabolic Disorders Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy Type
  • 9.3.3. Colombia Metabolic Disorders Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy Type

10. Middle East and Africa Metabolic Disorders Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metabolic Disorders Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy Type
  • 10.3.2. Saudi Arabia Metabolic Disorders Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy Type
  • 10.3.3. UAE Metabolic Disorders Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Metabolic Disorders Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Novo Nordisk A/S
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Eli Lilly and Company
• 14.3. Takeda Pharmaceutical Company Limited
• 14.4. Sanofi SA
• 14.5. Merck KGaA
• 14.6. AstraZeneca PLC
• 14.7. AbbVie Inc
• 14.8. Johnson & Johnson Services, Inc
• 14.9. Amgen Inc
• 14.10.BioMarin International Limited

15. Strategic Recommendations

16. About Us & Disclaimer